Free Trial
Jeffrey Walch

Jeffrey Walch Analyst Performance

Senior Research Analyst - Pharmaceutical at Sanford C. Bernstein

Jeffrey Walch is a stock analyst at Sanford C. Bernstein in the medical sector, covering 7 publicly traded companies. Over the past year, Jeffrey Walch has issued 17 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Jeffrey Walch's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jeffrey Walch's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
17 Last 0 Years
Buy Recommendations
29.41% 5 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy5.9%1 ratings
Buy23.5%4 ratings
Hold58.8%10 ratings
Sell11.8%2 ratings

Out of 17 total stock ratings issued by Jeffrey Walch at Sanford C. Bernstein, the majority (58.8%) have been Hold recommendations, followed by 23.5% Buy, 11.8% Sell, and 5.9% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
7 companies

Jeffrey Walch, an analyst at Sanford C. Bernstein, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Jeffrey Walch of Sanford C. Bernstein specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
71.4%
MED - DRUGS
2 companies
28.6%

Jeffrey Walch's Ratings History at Sanford C. Bernstein

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Nuvalent, Inc. stock logo
NUVL
Nuvalent
6/10/2026Reiterated Rating$123.35Outperform
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
6/9/2026Reiterated Rating$233.68Market Perform
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
6/5/2026Reiterated Rating$88.40Market Perform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
5/22/2026Initiated Coverage$155.50$221.00Outperform
Incyte Corporation stock logo
INCY
Incyte
5/21/2026Initiated Coverage$97.41$99.00Market Perform
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
5/21/2026Initiated Coverage$239.40$229.00Market Perform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
5/21/2026Initiated Coverage$153.73$151.00Market Perform
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
5/21/2026Initiated Coverage$90.93$96.00Market Perform
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
5/21/2026Initiated Coverage$17.47$7.70Underperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5/21/2026Initiated Coverage$101.24$189.00Outperform
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5/21/2026Initiated Coverage$101.24$189.00Outperform
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
5/21/2026Upgrade$92.14Hold
Incyte Corporation stock logo
INCY
Incyte
5/21/2026Upgrade$97.16Hold
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
5/21/2026Upgrade$239.83Hold
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5/21/2026Upgrade$102.12Strong-Buy
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
5/21/2026Upgrade$151.56Hold
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
5/21/2026Upgrade$16.62Strong Sell